Hims shares shoot up after weight-loss drug deal with Novo Nordisk
US telehealth group and Danish drugmaker have been in dispute over copycat medicines
Related reading
Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill
US telehealth group will sell product for $49 a month, a third that of its Danish competitor
Novo Nordisk ends Hims & Hers tie-up over copycat Wegovy drugs
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
Novo Nordisk sues Hims & Hers over copycat weight-loss drugs
Shares in US company fall 16% after FDA announces investigation into unregulated medication
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Hims & Hers is a brave bet on solving the disruptor’s dilemma
Plan to make longevity affordable means muscling in on territory occupied by drugs giants and pharmacies